



eGastroenterology

eGastroenterology is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

eGastroenterology is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<https://egastroenterology.bmj.com/>).

If you have any questions on BMJ Paediatrics Open's open peer review process please email info.egastro@bmj.com.



A new dimension in viral hepatitis research

Journal:	<i>eGastroenterology</i>
Manuscript ID	egastro-2024-100136
Article Type:	Perspective
Date Submitted by the Author:	05-Sep-2024
Complete List of Authors:	Cocca, Massimiliano; INSERM U1052 Testoni, Barbara; The Lyon Hepatology Institute EVEREST
Keywords:	Hepatitis, Viral, Human

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **A new dimension in viral hepatitis research**
4
5

6
7 *Perspective on*

8
9 *Cross et al. "Characterization of HBV and co-infection with HDV and HIV through spatial*
10 *transcriptomics"*
11
12

13
14
15 Massimiliano Cocca^{1,2,3*}, Barbara Testoni^{1,2,3*}
16
17

18
19
20 ¹INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon, Lyon, France
21

22 ²University of Lyon, Université Claude-Bernard (UCBL), Lyon, France
23

24 ³The Lyon Hepatology Institute EVEREST, Lyon, France
25
26

27
28 * both authors contributed equally; massimiliano.cocca@inserm.fr; barbara.testoni@inserm.fr
29
30

31
32 **Abbreviations:**

33
34 HBV, Hepatitis B virus

35
36 HDV, Hepatitis delta virus

37
38 HIV, human immune deficiency virus

39
40 CHB, chronic hepatitis B

41
42 HCC, hepatocellular carcinoma

43
44 WHO, World Health Organization

45
46 ATAC-Seq, assay for transposase accessible chromatin - sequencing

47
48 ChIP-Seq, chromatin immunoprecipitation - sequencing
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Chronic hepatitis B (CHB) is the leading cause of hepatocellular carcinoma (HCC) and a significant global health issue, affecting over 296 million people worldwide, with 15 million people co-infected with Hepatitis Delta virus (HDV) suffering accelerated disease progression.

Recent advances in single-cell sequencing and spatial transcriptomics offer promising insights to improve the understanding of the liver's immune responses and HBV-infected cell distribution, with the final goal being the achievement of an HBV "functional cure".

In this issue of *eGastroenterology*, Cross et al. utilized the GeoMx nanostring Digital Spatial Profiling (DSP) technology to study gene expression in liver tissues of three patients (one HBV-monoinfected, one HBV/HDV co-infected, and one HBV/HIV co-infected). Unlike other spatial transcriptomics techniques, GeoMx DSP allows targeted selection of specific tissue regions (ROIs) for analysis, enabling precise gene expression mapping. The study revealed spatially distinct transcriptomic signatures related to immune features and viral burden, identifying a component of under-investigated immune cells. Despite the small sample size, this proof-of-concept study demonstrates the feasibility of spatial transcriptomics in analyzing HBV infections. Future advances, such as integrating viral proteins and nucleic acids, will enhance understanding of spatial viral replication. Challenges in tissue processing, data analysis, and costs remain before spatial transcriptomics can be applied as a diagnostic tool, but ongoing multi-omics approaches offer promise for improved diagnosis and therapy.

1
2
3 Chronic hepatitis B (CHB) is the first cause of hepatocellular carcinoma (HCC) and a major
4 public health problem, being the most prevalent chronic infectious disease worldwide with
5 more than 296 million individuals concerned (1). Fifteen million chronic HBV carriers are also
6 co-infected with Hepatitis Delta virus (HDV), resulting in an accelerated progression to cirrhosis
7 and HCC. The management of HBV/HDV co-infected patients is limited by the low response
8 rate to interferon therapy and Bulevirtide, an entry inhibitor, has received a conditional approval
9 from EMA (2). Current treatments against CHB induce viral suppression but require life-long
10 regimens in most patients. “HBV functional cure”, defined as sustained loss of HBV surface
11 antigen (HBsAg) and HBV DNA off-therapy, is the holy grail of current therapeutic
12 development, since it is associated with improved liver disease outcomes (3). Eradicating or
13 silencing of HBV genomes coupled to re-educating the liver micro-environment are considered
14 key to establish a sustained immune control of the infection. The WHO estimates that 8% of
15 persons with HIV are also co-infected with HBV, a condition associated with accelerated liver
16 disease progression and mortality (4). Paradoxically, despite the HIV-induced
17 immunosuppression, rates of HBV functional cure are higher in HIV/HBV co-infected persons
18 compared to people infected with HBV alone (5)

19
20 A major obstacle to the development of innovative and efficient therapeutic interventions
21 against CHB is represented by the lack of comprehensive investigation on the interplay
22 between intrahepatic viral burden and immune responses in relationship with liver
23 microenvironment.

24
25 While it appears evident that the distribution of HBV-infected cells is not homogeneous across
26 the liver lobule, recent attempts using multiplex immunofluorescence approaches have
27 provided limited information on the interplay between viral burden and liver microenvironment
28 (6,7).

29
30 The implementation of fine liver aspirates (FNAs) coupled to single cell sequencing or high-
31 sensitive techniques for HBV detection has recently paved the way to groundbreaking studies
32 on liver HBV persistence and immune responses (8–10). However, FNAs do not preserve liver
33 tissue architecture, thus missing the liver spatial information.

1
2
3 Spatial transcriptomic has gained momentum in the last quinquennium (11), becoming
4 increasingly used either to enrich information provided by bulk RNA-seq or single cell RNA-
5 seq approaches through deconvolution methods (12,13), or to provide, by itself, a spatial
6 reference for single cell expression, cell to cell communication insights (14) and help
7 researchers to go from “causative loci” to “causative location”, when dealing with pathological
8 phenotypes.

9
10
11 In this issue of eGastroenterology, Cross et al. applied a spatial transcriptomic approach, using
12 the GeoMx nanostring Digital Spatial Profiling (DSP) technology to investigate the gene
13 expression patterns associated to selected topographies of HBV infected cells in the liver of
14 three representative chronically infected patients (one HBV-monoinfected, one HBV/HDV co-
15 infected and one HBV/HIV co-infected) (15).

16
17 Differently from other sequencing-based spatial transcriptomic techniques (16,17), which
18 provide a fixed grid of capture spots, the GeoMX DSP platform allow the manual definition of
19 specific areas of the tissue (i.e. Regions Of Interest – ROIs), where barcodes attached to tissue
20 mRNAs can be released and aspirated by a microcapillary pipette. These barcodes can be
21 collected and converted into a next-generation sequencing compatible library for direct
22 counting. In this way, barcodes (a surrogate for bound detection oligonucleotides) can be
23 mapped to ROIs to provide a digital readout of gene expression within the tissue context (18).
24 ROIs can be selected by the user to leverage any a-priori knowledge of the tissue/phenotype,
25 providing a “target sequencing”-like approach (18). Though the resolution achieved at the time
26 of writing is still in the order of 50-100 cells per ROI (almost an order of magnitude bigger than
27 the 10x Visium, its direct competitor (17)), the targeted ROI selection strategy allows for the
28 precise capture of gene expression profile of histologic structure of interest. Moreover,
29 fluorescently labeled antibodies can be used to segment discontinuous cells (e.g. HBsAg
30 staining and CD45 staining in Cross et al.) to perform differential expression analysis.
31
32 Conversely, this approach is not suited to obtain a map of gene expression across the entire
33 tissue and could introduce bias due to the manual selection of ROIs. Like its 10x counterpart,
34 the expression profiles generated by the GeoMX DSP still represent a composite, bulk-like,
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 collection of cells, therefore it is imperative to apply computational approaches to deconvolve
4
5 the cellular composition of the generated profiles.
6

7 The proof-of-concept study presented by Cross et al. provides an example of a state of the art
8
9 analysis workflow: 1) differentially expressed genes (DE) are identified comparing ROIs in a
10
11 'case-control' style, 2) Pathways over representation analysis is performed exploiting the Gene
12
13 Ontology datasets, 3) A weighted gene correlation network analysis (WGCNA) is applied to
14
15 the expression values to identify cluster of genes 'moving together', 4) and a cell deconvolution
16
17 method is used to increase the resolution to the picture the authors are providing.
18

19 This kind of workflow should be regarded as the standard approach to provide a solid starting
20
21 point to investigate a tissue micro-environment also in small collections of samples.
22
23

24 This proof-of-concept study has the merit of demonstrating the feasibility and utility of spatial
25
26 transcriptomic (ST) in analyzing gene expression patterns, immune cell composition and
27
28 biological processes at high resolution within the liver microenvironment. The use of anti-
29
30 HBsAg and CD45 immunostaining to drive ROI selection allowed the identification of tissue
31
32 regions with different balance between viral burden and extent of immune infiltration. Although
33
34 the small number of samples and the high intra- and inter-sample variability severely limit the
35
36 generalization of the conclusions, it is worth noting that spatially discrete transcriptomic
37
38 signatures relating to immune features could be identified. Moreover, insights were provided
39
40 on under-investigated immune subsets, namely $\gamma\delta$ T cells, $\alpha\beta$ T cells, mature B cells and
41
42 inflammatory macrophages, whose proportions differed between samples. Further advances
43
44 in the interpretations of these type of results will come once multiple viral proteins (e.g. HBsAg,
45
46 HBcAg, HDV antigens) and even viral nucleic acids would be included in the workflow, thus
47
48 allowing a precise understanding of spatial distribution of cells harboring active viral replication.
49
50 Besides the results provided by Cross et al in their study, which, limited in sample size as it is,
51
52 represents the first application of the GeoMx DSP technology on HBV samples with co-
53
54 infection, a question is still lingering: how can we leverage the insights provided by spatial
55
56 transcriptomic, to improve diagnosis and eventually tailor therapeutic interventions?
57
58
59
60

1
2
3 Many challenges remain to be addressed so that ST approaches could become a proper
4 diagnostic tool, mainly in the tissue processing and data analysis, but also from a cost-related
5 side. On a technical side, there is still the need of independent assessment of performances,
6 to quantify the contribution of biological and technical sources of variability. Moreover, the need
7 for benchmarks to ensure the stability of the platform and compatibility of data collected at
8 different times. Additionally, the data analysis has a long turnaround time, more consistent with
9 the research time-span, that with the one required for a laboratory developed test.
10
11

12
13
14
15
16
17 Ideally, the best approach would be to apply ST techniques to representative cohorts,
18 increasing, for example, the power to identify meaningful inter-groups variation by sampling
19 different regions from the same sample, generating expression profiles for a bigger
20 subpopulation of cells (obviously, this calls for the additional control of any batch effect
21 introduced, with additional steps of data normalization or QC). Results from the analyses
22 performed on cohorts, also related to response to treatments, could then inform researcher
23 and guide them to identify novel diagnostic biomarkers or drug targets that could be validated
24 using techniques already available in a laboratory contest, providing than an instrument that
25 will be cost-effective and more likely to be included in the diagnostic process (Figure 1).
26
27

28
29
30
31
32
33
34
35
36
37 The work from Cross et al. testifies of the “spatial” revolution occurring in the hepatology field
38 (14,19,20) and expected to transform basic and translation research also in viral hepatitis. The
39 use of FFPE material opens the possibility of investigating large stored collections of samples.
40
41
42
43 The implementation of multi-omics approaches, coupling proteomics, transcriptomics,
44 metabolomics and their integration with other modalities such as ATAC-seq or ChIP-seq is
45 already on the way and is expected to provide unprecedented insights into virus-host
46 interactions in the liver.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Competing interests:

M.C. has nothing to declare

B.T. receives funding from Assembly Biosciences, Beam Therapeutics, BlueJay Therapeutics, Aligos

Fundings:

M.C. and B.T. are supported by grants provided by the “Agence Nationale pour la Recherche sur le SIDA et les hepatites virales et les maladies infectieuses emergentes” (ANRS|MIE) under grant agreements ECTZ143165 and ECTZ210845, and by the French National Agency for Research (ANR, grant IHU EVEREST: ANR-23-IAHU-0008).

Patient and Public Involvement

Patients' involvement was not applicable to this type of manuscript.

Ethics Statement

The manuscript does not involve any human participants or animal subjects.

Contributorship:

MC and BT draft the manuscript, finalized it and created the figure. BT is the guarantor for the manuscript.

References:

1. Hepatitis B [Internet]. [cited 2024 Sep 4]. Available from: <https://www.who.int/news-room/fact-sheets/detail/hepatitis-b>
2. Brunetto MR, Ricco G, Negro F, Wedemeyer H, Yurdaydin C, Asselah T, et al. EASL Clinical Practice Guidelines on hepatitis delta virus. *J Hepatol.* 2023 Aug;79(2):433–60.
3. Lim SG, Baumert TF, Boni C, Gane E, Levrero M, Lok AS, et al. The scientific basis of combination therapy for chronic hepatitis B functional cure. *Nat Rev Gastroenterol Hepatol.* 2023 Apr;20(4):238–53.
4. Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Muñoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). *The Lancet.* 2002 Dec;360(9349):1921–6.

- 1
2
3 5. Chihota BV, Wandeler G, Chilengi R, Mulenga L, Chung RT, Bhattacharya D, et al.
4 High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency
5 Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia. *J Infect Dis*. 2020
6 Jan;221(2):218–22.
7
- 8
9
10
11 6. van Buuren N, Ramirez R, Turner S, Chen D, Suri V, Aggarwal A, et al. Characterization
12 of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection.
13 *JHEP Rep*. 2022 Jan;4(1):100388.
14
- 15
16
17
18 7. Aggarwal A, Odorizzi PM, Brodbeck J, Buuren N van, Moon C, Chang S, et al.
19 Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and
20 treatment-mediated reductions in HBV core-positive cells. *JHEP Rep* [Internet]. 2023 Apr [cited
21 2024 Sep 2];5(4). Available from: [https://www.jhep-reports.eu/article/S2589-5559\(22\)00236-](https://www.jhep-reports.eu/article/S2589-5559(22)00236-1/fulltext)
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
8. Genshaft AS, Subudhi S, Keo A, Sanchez Vasquez JD, Conceição-Neto N, Mahamed
D, et al. Single-cell RNA sequencing of liver fine-needle aspirates captures immune diversity
in the blood and liver in chronic hepatitis B patients. *Hepatology*. 2023 Nov;78(5):1525.
9. Kim SC, Wallin JJ, Ghosheh Y, Zahoor MA, Vasquez JDS, Nkongolo S, et al. Efficacy
of antiviral therapy and host–virus interactions visualised using serial liver sampling with fine-
needle aspirates. *JHEP Rep* [Internet]. 2023 Sep [cited 2024 Sep 2];5(9). Available from:
[https://www.jhep-reports.eu/article/S2589-5559\(23\)00148-9/fulltext](https://www.jhep-reports.eu/article/S2589-5559(23)00148-9/fulltext)
10. Testoni B, Suarez AAR, Battisti A, Plissonnier ML, Heil M, Fontanges T, et al.
Evaluation of the HBV liver reservoir with fine needle aspirates. *JHEP Rep* [Internet]. 2023 Oct
[cited 2024 Sep 2];5(10). Available from: [https://www.jhep-reports.eu/article/S2589-](https://www.jhep-reports.eu/article/S2589-5559(23)00172-6/fulltext)
5559(23)00172-6/fulltext
11. Marx V. Method of the Year: spatially resolved transcriptomics. *Nat Methods*. 2021
Jan;18(1):9–14.
12. Li Y, Luo Y. STdGCN: spatial transcriptomic cell-type deconvolution using graph
convolutional networks. *Genome Biol*. 2024 Aug;25(1):206.


- 1
2
3 13. Zhu S, Kubota N, Wang S, Wang T, Xiao G, Hoshida Y. STIE: Single-cell level
4 deconvolution, convolution, and clustering in in situ capturing-based spatial transcriptomics.
5 Nat Commun. 2024 Aug;15(1):7559.
6
7
- 8
9 14. Ding J, Li L, Lu Q, Venegas J, Wang Y, Wu L, et al. SpatialCTD: A Large-Scale Tumor
10 Microenvironment Spatial Transcriptomic Dataset to Evaluate Cell Type Deconvolution for
11 Immuno-Oncology. J Comput Biol [Internet]. 2024 Aug [cited 2024 Sep 2]; Available from:
12 <https://www.liebertpub.com/doi/10.1089/cmb.2024.0532>
13
14
- 15 15. Cross A, Harris JM, Arbe-Barnes E, Nixon C, Dhairyawan R, Hall A, et al.
16 Characterisation of HBV and co-infection with HDV and HIV through spatial transcriptomics.
17 eGastroenterology [Internet]. 2024 Jul [cited 2024 Sep 2];2(3). Available from:
18 <https://egastroenterology.bmj.com/content/2/3/e100067>
19
20
- 21 16. Stickels RR, Murray E, Kumar P, Li J, Marshall JL, Di Bella DJ, et al. Highly sensitive
22 spatial transcriptomics at near-cellular resolution with Slide-seqV2. Nat Biotechnol. 2021
23 Mar;39(3):313–9.
24
25
- 26 17. Ståhl PL, Salmén F, Vickovic S, Lundmark A, Navarro JF, Magnusson J, et al.
27 Visualization and analysis of gene expression in tissue sections by spatial transcriptomics.
28 Science. 2016 Jul;353(6294):78–82.
29
30
- 31 18. Merritt CR, Ong GT, Church SE, Barker K, Danaher P, Geiss G, et al. Multiplex digital
32 spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol. 2020 May;38(5):586–99.
33
34
- 35 19. Guilliams M, Bonnardel J, Haest B, Vanderborght B, Wagner C, Remmerie A, et al.
36 Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage
37 niches. Cell. 2022 Jan;185(2):379-396.e38.
38
39
- 40 20. Yu X, Gong Q, Yu D, Chen Y, Jing Y, Zoulim F, et al. Spatial transcriptomics reveals a
41 low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss.
42 Gut. 2024 May;73(5):797–809.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Workflow aiming at implementing spatial approaches into clinical development.


Created with Biorender.com

FRESH OR ARCHIVED TISSUE




- Biopsy
- Surgery
- FNA
- Slides
- Bio-banks

SPATIAL APPROACH





BULK APPROACH



REPRESENTATIVE COHORTS STUDIES

eGastroenterology



LABORATORY DEVELOPED TESTS



- Sequencing
- Biomarker analyses
- Rapid tests

CLINICAL IMPLEMENTATION



- POC clinical studies
- Preventive diagnosis
- Therapy recommendation
- Follow up strategies